Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12960116,area under the concentration-time curve,"Patients received suramin followed by paclitaxel (175-200 mg/m(2)) and carboplatin area under the concentration-time curve of 6 mg/ml/min, every 3 weeks.",Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),[mg] / [min·ml],6,16396,DB04786,Suramin
>,12960116,peak concentrations,The initial suramin dose resulted in the targeted concentrations of 10-20 microM at 48 h in 5 of the first 6 patients treated but also resulted in peak concentrations > 50 microM in all patients.,Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),μM,50,16397,DB04786,Suramin
,12960116,time to tumor progression,"The median time to tumor progression is 8.5 months (range, 3-27+ months) for 12 evaluable patients.",Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12960116/),month,8.5,16398,DB04786,Suramin
,8622081,overall survival time,"The median overall survival time for all patients is 31 weeks (95% confidence interval [CI], 23 to 51).",Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8622081/),weeks,31,36570,DB04786,Suramin
,11432894,time to progression,"Median time to progression was 55 days (range, 17 to 242 days) and median survival was 191 days (range, 42 to 811 days).","Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432894/),d,55,40716,DB04786,Suramin
,11432894,survival,"Median time to progression was 55 days (range, 17 to 242 days) and median survival was 191 days (range, 42 to 811 days).","Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11432894/),d,191,40717,DB04786,Suramin
,3005375,plasma half-life,"After the last dose, the plasma half-life of suramin was 44 to 54 days.",Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005375/),d,44 to 54,54616,DB04786,Suramin
greater,3005375,Total plasma levels,Total plasma levels of suramin were greater than 100 micrograms/mL for several weeks.,Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3005375/),[μg] / [ml],100,54617,DB04786,Suramin
greater,7666077,peak plasma suramin concentrations,"Patients were to be removed from the fixed dosing schedule if, after day 5, three consecutive peak plasma suramin concentrations were greater than 300 micrograms/mL.",Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666077/),[μg] / [ml],300,64517,DB04786,Suramin
> or =,7666077,peak plasma suramin concentrations,No patient had treatment discontinued due to repeated peak plasma suramin concentrations > or = 300 micrograms/mL.,Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666077/),[μg] / [ml],300,64518,DB04786,Suramin
,7666077,survival time,The estimated median survival time in 38 assessable patients with HRPC was 18.8 months.,Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666077/),month,18.8,64519,DB04786,Suramin
,7666077,time to progression,"The estimated median time to progression in 35 patients, for whom data were available, was 10.1 months.",Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666077/),month,10.1,64520,DB04786,Suramin
,15587928,distribution half-life,"Plasma concentrations declined biexponentially following intravenous administration, with a distribution half-life of approximately 2 h and an estimated terminal half-life of 276 h.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),h,2,69469,DB04786,Suramin
,15587928,terminal half-life,"Plasma concentrations declined biexponentially following intravenous administration, with a distribution half-life of approximately 2 h and an estimated terminal half-life of 276 h.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),h,276,69470,DB04786,Suramin
,15587928,maximal plasma concentrations,"Suramin absorption following oral gavage was variable and incomplete with mean maximal plasma concentrations of 9.04, 72.6, and 64.4 microg/ml at doses of 100, 300, and 500 mg/kg, respectively.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),[μg] / [ml],9.04,69471,DB04786,Suramin
,15587928,maximal plasma concentrations,"Suramin absorption following oral gavage was variable and incomplete with mean maximal plasma concentrations of 9.04, 72.6, and 64.4 microg/ml at doses of 100, 300, and 500 mg/kg, respectively.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),[μg] / [ml],72.6,69472,DB04786,Suramin
,15587928,maximal plasma concentrations,"Suramin absorption following oral gavage was variable and incomplete with mean maximal plasma concentrations of 9.04, 72.6, and 64.4 microg/ml at doses of 100, 300, and 500 mg/kg, respectively.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),[μg] / [ml],64.4,69473,DB04786,Suramin
<,15587928,Oral bioavailability,"Oral bioavailability, calculated using the clearance of the intravenous tracer dose, was <3% at all three dose levels.",Suramin as a chemosensitizer: oral pharmacokinetics in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15587928/),%,3,69474,DB04786,Suramin
,21590254,plasma concentrations,Suramin plasma concentrations ranged from 155 to 258 mu g/ml over the 14-day therapy period with tumor concentrations in the 53-241 mu g/g wet weight range.,Clinically relevant suramin dosing regimen in mice with no effects against PC-3 prostate xenografts. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21590254/),,155 to 258,83318,DB04786,Suramin
,9230794,re,Traced study patients had a relapse rate of 4.1%.,Attempt to correlate urine arsenic excretion with clinical course during melarsoprol therapy of patients with Rhodesian trypanosomiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9230794/),,4.1,105161,DB04786,Suramin
,9230794,total urine arsenic output,The range of means of total urine arsenic output between the three treatment courses was 356-511 micrograms.,Attempt to correlate urine arsenic excretion with clinical course during melarsoprol therapy of patients with Rhodesian trypanosomiasis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9230794/),μg,356-511,105162,DB04786,Suramin
,9626459,mean plasma concentrations,Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22.,"Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],210,111142,DB04786,Suramin
,9626459,mean plasma concentrations,Suramin was administered to 49 patients in a Phase I cancer trial with real-time pharmacokinetic monitoring and dose individualization to achieve targeted mean plasma concentrations of 210 and 155 mg/liter during the 7-day period between days 15 and 22.,"Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],155,111143,DB04786,Suramin
,9626459,averaged,"Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter.","Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],210,111144,DB04786,Suramin
,9626459,averaged,"Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter.","Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],155,111145,DB04786,Suramin
,9626459,plasma concentrations,"Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter.","Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],210,111146,DB04786,Suramin
,9626459,plasma concentrations,"Pharmacokinetic sampling after doses on days 1, 3, 5, and 8 was used to modify weekly suramin doses, beginning on day 15, in an attempt to achieve specific averaged plasma concentrations of 210 and 155 mg/liter.","Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],155,111147,DB04786,Suramin
excess,9626459,peak plasma suramin concentrations,"Patients with peak plasma suramin concentrations in excess of 350 mg/liter may be more likely to experience neurotoxicity (P = 0.06), but there was no statistically significant effect of peak suramin concentration or of cumulative dose.","Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9626459/),[mg] / [l],350,111148,DB04786,Suramin
>,9010008,peak concentrations,"We conclude that when suramin is used at peak concentrations of > or = 350 micrograms ml-1 its administration is associated with two patterns of neuropathy, a distal axonal neuropathy and an inflammatory demyelinating neuropathy that is partially reversible.",A prospective study of suramin-induced peripheral neuropathy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9010008/),[μg] / [ml],350,118202,DB04786,Suramin
,9681668,apparent volume of distribution,The apparent volume of distribution (median 20.6 l) was comparable to that reported for patients with prostatic carcinoma.,Clinical pharmacokinetics of suramin in patients with onchocerciasis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681668/),l,20.6,121228,DB04786,Suramin
,9681668,plasma clearance,"Elimination from patients with onchocerciasis was relatively slow (median plasma clearance 6.2 ml x h(-1), median terminal elimination half-life 91.8 days).",Clinical pharmacokinetics of suramin in patients with onchocerciasis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681668/),[ml] / [h],6.2,121229,DB04786,Suramin
,9681668,terminal elimination half-life,"Elimination from patients with onchocerciasis was relatively slow (median plasma clearance 6.2 ml x h(-1), median terminal elimination half-life 91.8 days).",Clinical pharmacokinetics of suramin in patients with onchocerciasis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9681668/),d,91.8,121230,DB04786,Suramin
,1403059,terminal half-life,Suramin is an anticancer agent with a narrow therapeutic window and a terminal half-life of 45 to 55 days.,Suramin: rapid loading and weekly maintenance regimens for cancer patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403059/),d,45 to 55,151185,DB04786,Suramin
,1403059,serum trough concentrations,"Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 micrograms/mL, while preventing mean peak concentrations of more than 300 micrograms/mL.",Suramin: rapid loading and weekly maintenance regimens for cancer patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403059/),[μg] / [ml],150,151186,DB04786,Suramin
more,1403059,peak concentrations,"Maintenance treatment, which used the weekly administration of suramin during a 6-hour period, seemed to be able to maintain mean suramin serum trough concentrations of 150 micrograms/mL, while preventing mean peak concentrations of more than 300 micrograms/mL.",Suramin: rapid loading and weekly maintenance regimens for cancer patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1403059/),[μg] / [ml],300,151187,DB04786,Suramin
,10430255,progression free,Median progression free and overall survival were both 8 months.,Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10430255/),month,8,155777,DB04786,Suramin
,22729159,objective response rate (ORR),"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),%,23,162353,DB04786,Suramin
,22729159,progression-free survival,"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),month,3.4,162354,DB04786,Suramin
,22729159,overall survival,"In phase II, the objective response rate (ORR) was 23 % (95 % CI 8-45 %), the median progression-free survival was 3.4 months (95 % CI 2.1-4.9 months), and the median overall survival was 11.2 months (95 % CI 6.6-16.0 months).",Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22729159/),month,11.2,162355,DB04786,Suramin
,16715360,terminal half-life,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),h,202,163342,DB04786,Suramin
,16715360,total body clearance,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),[l] / [(m)^2·h],0.029,163343,DB04786,Suramin
,16715360,total body clearance,The chemosensitizing suramin dose showed a terminal half-life of 202 h and a total body clearance of 0.029 L h(-1) m(-2) (higher than the 0.013 L h(-1) m(-2) value for MTD of suramin).,Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16715360/),[l] / [(m)^2·h],0.013,163344,DB04786,Suramin
,18632723,area under the concentration-time curve,Patients received paclitaxel (Taxol) (200 mg/m(2)) and carboplatin (area under the concentration-time curve 6 mg/ml/min) every 3 weeks.,Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),[mg] / [min·ml],6,179207,DB04786,Suramin
,18632723,response rate,"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),%,36,179208,DB04786,Suramin
,18632723,progression-free survival,"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),month,6.4,179209,DB04786,Suramin
,18632723,overall survival (OS),"In arm A, response evaluation criteria in solid tumors (RECIST) response rate was 36% (95% confidence interval 22% to 54%; two complete, 12 partial); 15 patients (38%) had disease stabilization for > or =4 months; median progression-free survival (intention to treat) was 6.4 months; median overall survival (OS) 10.4 months and 1-year survival rate 38%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),month,10.4,179210,DB04786,Suramin
,18632723,OS,"In arm B, no RECIST responses occurred; four patients had disease stabilization for > or =4 months; median OS was 132 days and 1-year survival rate 7%.",Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18632723/),d,132,179211,DB04786,Suramin
greater,7666078,sustained peak plasma concentrations,"However, questions about the relationship of severe neurotoxicity to sustained peak plasma concentrations greater than 300 micrograms/mL raised concerns that this drug could not be safely administered without adaptive control.",Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666078/),[μg] / [ml],300,201166,DB04786,Suramin
,7666078,peak plasma concentration,"The mean peak plasma concentration following the loading dose at a dose level of 1,730 mg/m2 was 933 micrograms/mL (26% coefficient of variation), and the mean trough concentration was 139 micrograms/mL (40% CV) on day 1 of cycle 2 [corrected].",Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666078/),[μg] / [ml],933,201167,DB04786,Suramin
,7666078,trough concentration,"The mean peak plasma concentration following the loading dose at a dose level of 1,730 mg/m2 was 933 micrograms/mL (26% coefficient of variation), and the mean trough concentration was 139 micrograms/mL (40% CV) on day 1 of cycle 2 [corrected].",Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666078/),[μg] / [ml],139,201168,DB04786,Suramin
greater,7666080,area under the curve (AUC),"Pharmacologic variables associated with the development of polyneuropathy included total cumulative suramin dose, duration of exposure to plasma concentrations greater than 200 micrograms/mL, and area under the curve (AUC) greater than 200 micrograms/mL.",Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666080/),[μg] / [ml],200,201786,DB04786,Suramin
,7666080,total,"Future clinical trials of suramin should be designed in such a way as to limit the total cumulative dose to < or = 157 mg/kg given over a period of > or = 8 weeks, limit the period of exposure to plasma suramin concentrations greater than 200 micrograms/mL to < or = 25 days, and limit the AUC greater than 200 micrograms/mL to < or = 48,000 mg.h/AL.",Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666080/),mg,157,201787,DB04786,Suramin
greater,7666080,AUC,"Future clinical trials of suramin should be designed in such a way as to limit the total cumulative dose to < or = 157 mg/kg given over a period of > or = 8 weeks, limit the period of exposure to plasma suramin concentrations greater than 200 micrograms/mL to < or = 25 days, and limit the AUC greater than 200 micrograms/mL to < or = 48,000 mg.h/AL.",Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666080/),[μg] / [ml],200,201788,DB04786,Suramin
<,7666080,AUC,"Future clinical trials of suramin should be designed in such a way as to limit the total cumulative dose to < or = 157 mg/kg given over a period of > or = 8 weeks, limit the period of exposure to plasma suramin concentrations greater than 200 micrograms/mL to < or = 25 days, and limit the AUC greater than 200 micrograms/mL to < or = 48,000 mg.h/AL.",Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666080/),[h·mg] / [al],"48,000",201789,DB04786,Suramin
,7993834,trough serum level,Subsequent patients received suramin 500 mg/m2 as a one hour intravenous infusion thrice weekly until a trough serum level of 200 micrograms/ml was achieved.,Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993834/),[μg] / [ml],200,208079,DB04786,Suramin
up to,7993834,peak serum levels,"Despite peak serum levels of up to 506 micrograms/ml, no serious toxicity was seen.",Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7993834/),[μg] / [ml],506,208080,DB04786,Suramin
,14692025,overall survival time,The median overall survival time was 15.3 months.,A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692025/),month,15.3,215963,DB04786,Suramin
,14692025,response rate,"Among the 12 evaluable patients who previously had received chemotherapy, the PSA response rate was 42%; one response was observed among 4 patients with measurable disease, and the median survival was 12 months.",A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692025/),%,42,215964,DB04786,Suramin
,1394202,time to target level,"This showed a wide interpatient variation in time to target level (median, 13.8 days), volume of distribution (median, 15.2 liters/m2), and t1/2-beta (median, 20.6 days).","Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394202/),d,13.8,220657,DB04786,Suramin
,1394202,volume of distribution,"This showed a wide interpatient variation in time to target level (median, 13.8 days), volume of distribution (median, 15.2 liters/m2), and t1/2-beta (median, 20.6 days).","Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394202/),[l] / [m2],15.2,220658,DB04786,Suramin
,1394202,t1/2-beta,"This showed a wide interpatient variation in time to target level (median, 13.8 days), volume of distribution (median, 15.2 liters/m2), and t1/2-beta (median, 20.6 days).","Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1394202/),d,20.6,220659,DB04786,Suramin
,1727387,time to peak concentration,"A fixed rate continuous infusion schedule was used in seven patients, and the time to peak concentration (280-300 micrograms/ml) ranged from 7.7-21 days (mean, 13.2 days) with a decline to 150 micrograms/ml in 3-22 days (mean, 11 days).",Use of adaptive control with feedback to individualize suramin dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),[μg] / [ml],280-300,223302,DB04786,Suramin
,1727387,time to peak concentration,"A fixed rate continuous infusion schedule was used in seven patients, and the time to peak concentration (280-300 micrograms/ml) ranged from 7.7-21 days (mean, 13.2 days) with a decline to 150 micrograms/ml in 3-22 days (mean, 11 days).",Use of adaptive control with feedback to individualize suramin dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),d,13.2,223303,DB04786,Suramin
,1727387,time to peak concentration,"A fixed rate continuous infusion schedule was used in seven patients, and the time to peak concentration (280-300 micrograms/ml) ranged from 7.7-21 days (mean, 13.2 days) with a decline to 150 micrograms/ml in 3-22 days (mean, 11 days).",Use of adaptive control with feedback to individualize suramin dosing. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),,11,223304,DB04786,Suramin
,1727387,volume of the central compartment,"The mean volume of the central compartment was 4.5 +/- 6.7 liters/m2, volume of the peripheral compartment 10.6 +/- 1.4 liters/m2, distributional half-life 25 +/- 5.4 h, and elimination half-life 29.7 +/- 6.9 h.",Use of adaptive control with feedback to individualize suramin dosing. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),[l] / [m2],4.5,223305,DB04786,Suramin
,1727387,volume of the peripheral compartment,"The mean volume of the central compartment was 4.5 +/- 6.7 liters/m2, volume of the peripheral compartment 10.6 +/- 1.4 liters/m2, distributional half-life 25 +/- 5.4 h, and elimination half-life 29.7 +/- 6.9 h.",Use of adaptive control with feedback to individualize suramin dosing. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),[l] / [m2],10.6,223306,DB04786,Suramin
,1727387,distributional half-life,"The mean volume of the central compartment was 4.5 +/- 6.7 liters/m2, volume of the peripheral compartment 10.6 +/- 1.4 liters/m2, distributional half-life 25 +/- 5.4 h, and elimination half-life 29.7 +/- 6.9 h.",Use of adaptive control with feedback to individualize suramin dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),h,25,223307,DB04786,Suramin
,1727387,elimination half-life,"The mean volume of the central compartment was 4.5 +/- 6.7 liters/m2, volume of the peripheral compartment 10.6 +/- 1.4 liters/m2, distributional half-life 25 +/- 5.4 h, and elimination half-life 29.7 +/- 6.9 h.",Use of adaptive control with feedback to individualize suramin dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),h,29.7,223308,DB04786,Suramin
,1727387,distributional half-life,"The resulting distributional half-life of 22.3 +/- 2.7 h and elimination half-life of 28.2 +/- 5.0 h were similar, reflecting the intensive sampling.",Use of adaptive control with feedback to individualize suramin dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),h,22.3,223309,DB04786,Suramin
,1727387,elimination half-life,"The resulting distributional half-life of 22.3 +/- 2.7 h and elimination half-life of 28.2 +/- 5.0 h were similar, reflecting the intensive sampling.",Use of adaptive control with feedback to individualize suramin dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1727387/),h,28.2,223310,DB04786,Suramin
,8453691,distribution phase,A distribution phase of 3.8 h was found.,Evidence of an absorption phase after short intravenous suramin infusions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8453691/),h,3.8,237566,DB04786,Suramin
,7666076,overall times to disease progression,"The overall times to disease progression and survival were 170 and 492 days, respectively.",Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666076/),d,170,239943,DB04786,Suramin
,7666076,survival,"The overall times to disease progression and survival were 170 and 492 days, respectively.",Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666076/),d,492,239944,DB04786,Suramin
,10367107,Cmax,"The plasma levels were significantly higher after oral administration of drug than after intraperitoneal route (33.8 micrograms/ml compared with 19.0 micrograms/ml for Cmax, 158714 micrograms.h/l compared with 96057 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[μg] / [ml],33.8,240284,DB04786,Suramin
,10367107,Cmax,"The plasma levels were significantly higher after oral administration of drug than after intraperitoneal route (33.8 micrograms/ml compared with 19.0 micrograms/ml for Cmax, 158714 micrograms.h/l compared with 96057 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[μg] / [ml],19.0,240285,DB04786,Suramin
,10367107,AUC,"The plasma levels were significantly higher after oral administration of drug than after intraperitoneal route (33.8 micrograms/ml compared with 19.0 micrograms/ml for Cmax, 158714 micrograms.h/l compared with 96057 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[h·μg] / [l],158714,240286,DB04786,Suramin
,10367107,AUC,"The plasma levels were significantly higher after oral administration of drug than after intraperitoneal route (33.8 micrograms/ml compared with 19.0 micrograms/ml for Cmax, 158714 micrograms.h/l compared with 96057 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[h·μg] / [l],96057,240287,DB04786,Suramin
,10367107,Tmax,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),h,2,240288,DB04786,Suramin
,10367107,Tmax,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),h,4,240289,DB04786,Suramin
,10367107,Tmax,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[μg] / [ml],19.9,240290,DB04786,Suramin
,10367107,Cmax,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[μg] / [ml],19.9,240291,DB04786,Suramin
,10367107,Cmax,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[μg] / [ml],33.8,240292,DB04786,Suramin
,10367107,AUC,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[h·μg] / [l],95547,240293,DB04786,Suramin
,10367107,AUC,"When suramin (CAS 145-63-1) was administered 24 h before oral administration of megazol, megazol absorption was accelerated (2 h compared with 4 h for Tmax) but the amount absorbed was lower (19.9 micrograms/ml compared with 33.8 micrograms/ml for Cmax and 95547 micrograms.h/l vs 158714 micrograms.h/l for AUC).","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[h·μg] / [l],158714,240294,DB04786,Suramin
,10367107,apparent volume of distribution,"In the infected mice previously treated with suramin, all estimated pharmacokinetic parameters of plasma megazol were significantly modified, in particularly an increase in the apparent volume of distribution (5.6 l/kg compared with 0.9 l/kg) with a prolongation of the elimination half-life (3 h compared with 0.7 h) of megazol.","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[l] / [kg],5.6,240295,DB04786,Suramin
,10367107,apparent volume of distribution,"In the infected mice previously treated with suramin, all estimated pharmacokinetic parameters of plasma megazol were significantly modified, in particularly an increase in the apparent volume of distribution (5.6 l/kg compared with 0.9 l/kg) with a prolongation of the elimination half-life (3 h compared with 0.7 h) of megazol.","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),[l] / [kg],0.9,240296,DB04786,Suramin
,10367107,elimination half-life,"In the infected mice previously treated with suramin, all estimated pharmacokinetic parameters of plasma megazol were significantly modified, in particularly an increase in the apparent volume of distribution (5.6 l/kg compared with 0.9 l/kg) with a prolongation of the elimination half-life (3 h compared with 0.7 h) of megazol.","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),h,3,240297,DB04786,Suramin
,10367107,elimination half-life,"In the infected mice previously treated with suramin, all estimated pharmacokinetic parameters of plasma megazol were significantly modified, in particularly an increase in the apparent volume of distribution (5.6 l/kg compared with 0.9 l/kg) with a prolongation of the elimination half-life (3 h compared with 0.7 h) of megazol.","Pharmacokinetics, metabolism and excretion of megazol, a new potent trypanocidal drug in animals. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10367107/),h,0.7,240298,DB04786,Suramin
,7159399,half-life,The plasma clearance of intravenously injected 125I-labelled mitochondrial malate dehydrogenase (half-life 7 min) was not influenced by previous injection of suramin and/or leupeptin (inhibitors of intralysosomal proteolysis).,Endocytosis and breakdown of mitochondrial malate dehydrogenase in the rat in vivo. Effects of suramin and leupeptin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159399/),min,7,244626,DB04786,Suramin
,7159399,rates,We found that Kupffer cells and parenchymal cells had endocytosed the enzyme at rates corresponding to 9530 and 156 ml of plasma/day per g of cell protein respectively.,Endocytosis and breakdown of mitochondrial malate dehydrogenase in the rat in vivo. Effects of suramin and leupeptin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159399/),ml,9530,244627,DB04786,Suramin
,7159399,rates,We found that Kupffer cells and parenchymal cells had endocytosed the enzyme at rates corresponding to 9530 and 156 ml of plasma/day per g of cell protein respectively.,Endocytosis and breakdown of mitochondrial malate dehydrogenase in the rat in vivo. Effects of suramin and leupeptin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159399/),ml,156,244628,DB04786,Suramin
,7666079,duration of response,The median duration of response was 12 months.,Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7666079/),month,12,246781,DB04786,Suramin
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),h,2,254374,DB04786,Suramin
,17063712,half-lives,The pharmacokinetics of low-dose suramin followed a 2-compartment model with half-lives of 2 h and 6 days.,Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),d,6,254375,DB04786,Suramin
,17063712,distribution volume,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[l] / [kg],0.34,254376,DB04786,Suramin
,17063712,clearance,"The distribution volume was a 0.34 +/- 0.12 L/kg, and clearance was 1.86 +/- 0.76 mL/kg/h.",Phase I evaluation of low-dose suramin as chemosensitizer of doxorubicin in dogs with naturally occurring cancers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17063712/),[ml] / [h·kg],1.86,254377,DB04786,Suramin
